Skip to main content
Premium Trial:

Request an Annual Quote

Progenika to Develop Companion Dx for AMT Gene Therapy

NEW YORK (GenomeWeb News) – Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma plan to develop and market a diagnostic tool to rapidly diagnose patients who have lipoprotein lipase deficiency (LPLD) and may be candidates for an AMT therapeutic.

AMT said today that it will collaborate with Progenika to develop the LPLchip, which is based on Progenika's DNA-chip technology, to diagnose patients with complete and partial LPLD who may benefit from treatment with AMT's Glybera, a gene therapy.

AMT has released clinical data that it said show that Glybera can produce long-term health benefits for LPLD patients and can reduce acute pancreatitits, a complication of the disease. AMT plans to file the therapy for marketing in Europe by the end of this year.

"This collaborative project demonstrates how DNA-based diagnostics and highly targeted gene therapy can be combined to bring personalized medicine to patient groups whose medical needs were previously unmet," Progenika CEO Antonio Martinez said in a statement.